| Identification | Back Directory | [Name]
MOEXIPRILAT HYDRATE | [CAS]
103775-14-0 | [Synonyms]
RS 10029
Moexiprilat
Moexipril Related CoMpound A
2-[2-(1-Carboxy-3-phenyl-propylamino)-propionyl]-6,7-dimethoxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic Acid Hydrate
(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-phenylpropyl]aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid
(3S)-2-[(2S)-2-[[(1S)-1-Carboxy-3-(phenyl-d5)propyl]aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid
[3S-[2[R*(R*)],3R*]]-2-[2-[(1-
Carboxy-3-phenylpropyl)aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid
[3S-[2[R*(R*)],3R*]]-2-[2-[(1-
Carboxy-3-(phenyl-d5)propyl)aMino]-1-oxopropyl]-1,2,3,4-tetrahydro-6,7-diMethoxy-3-isoquinolinecarboxylic Acid | [Molecular Formula]
C25H30N2O7 | [MDL Number]
MFCD00865812 | [MOL File]
103775-14-0.mol | [Molecular Weight]
470.51 |
| Chemical Properties | Back Directory | [Appearance]
White Crystalline Solid | [Melting point ]
145-1700C | [storage temp. ]
Hygroscopic, -20°C Freezer, Under Inert Atmosphere | [solubility ]
DMSO: soluble
Methanol: soluble | [Major Application]
pharmaceutical | [InChIKey]
CMPAGYDKASJORH-YSSFQJQWSA-N | [SMILES]
N2([C@@H](Cc3c(cc(c(c3)OC)OC)C2)C(=O)O)C(=O)[C@@H](N[C@@H](CCc1ccccc1)C(=O)O)C |
| Hazard Information | Back Directory | [Chemical Properties]
White Crystalline Solid | [Uses]
Analogue of Quinapril | [Uses]
Angiotensin converting enzyme (ACE) inhibitor; dimethoxy analog of Quinapril. Antihypertensive. | [References]
[1] O EDLING. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.[J]. Journal of Pharmacology and Experimental Therapeutics, 1995, 275 2: 854-863.
[2] RYAN T. CAMERON . Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)[J]. Biochemical pharmacology, 2013, 85 9: Pages 1297-1305. DOI: 10.1016/j.bcp.2013.02.026
[3] C GROHÉ. Angiotensin converting enzyme inhibition modulates cardiac fibroblast growth.[J]. Journal of Hypertension, 1998, 16 3: 377-384. DOI: 10.1097/00004872-199816030-00015
[4] VAN EICKELS MARTIN. The influence of oestrogen-deficiency and ACE inhibition on the progression of myocardial hypertrophy in spontaneously hypertensive rats[J]. European Journal of Heart Failure, 2005, 7 7: 1079-1084. DOI: 10.1016/j.ejheart.2005.03.004 |
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Alfa Chemistry
|
| Tel: |
+1 (201) 478-8534 |
| Website: |
www.alfa-chemistry.com |
|